TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03009981
Drug: LHRH Analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1.
Study: NCT02328300
Drug: FLT PET/MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
Study: NCT03120234
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03120234
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: o.9% normal saline will be used instead of ketamine
Study: NCT03915938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in an identical way than ketamine.
Study: NCT01904058
Drug: LUM001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01904058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03079921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL bag of Normal Saline Solution (NSS).
Study: NCT02717611
Drug: ACP-196 (acalabrutinib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP-196 100 mg to be administered orally (PO) twice a day BID.
Study: NCT03065309
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus dose
Study: NCT03964090
Drug: TEDD-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
Study: NCT03964090
Drug: TEDDI-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
Study: NCT03964090
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
Study: NCT03980483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
Study: NCT03980483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cap (containing lactose) to be administered orally.
Study: NCT02001558
Drug: Microcyn
Normalized name: MICROCYN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
Study: NCT01864018
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00985478
Drug: SLV342
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg once daily - Maximal Tolerated Dose
Study: NCT00985478
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01479127
Drug: ABT-SLV187
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01479127
Drug: Oral Levodopa/Carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; contains 100 mg levodopa and 10 mg carbidopa
Study: NCT00531973
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
Study: NCT02427880
Drug: Acetazolamide and Hydrochlorothiazide Followed by Furosemide
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02427880
Drug: Furosemide and Hydrochlorothiazide Followed by Furosemide
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03434197
Drug: Diclofenac diethylamine
Normalized name: diclofenac diethylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
Study: NCT04073498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered by SC injection according to cohort dosing instructions.
Study: NCT04023552
Drug: TQJ230
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQJ230 80 mg injected monthly administered subcutaneously
Study: NCT04023552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
Study: NCT00413244
Drug: AndroGel 5 Grams
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
Study: NCT00413244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
Study: NCT03330288
Drug: Theraflex, BAY 874017
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
Study: NCT02917733
Drug: LY3039478
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00140933
Drug: MK0966; rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00140933
Drug: Comparator: diclofenac, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653872
Drug: AZD7986
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, single dose, dilution from concentrate
Study: NCT04125888
Drug: Allergy immunotherapy (AIT)
Normalized name: Callergy Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy for different types of allergies
Study: NCT04633577
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT02978326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
Study: NCT00837356
Drug: Advate®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
Study: NCT04195997
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin during left atrial appendage occlusion.
Study: NCT01775761
Drug: Period 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Study: NCT00991198
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no O2
Study: NCT00642538
Drug: MKC253 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder, prandial
Study: NCT00642538
Drug: Technosphere Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder, prandial
Study: NCT00642538
Drug: subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10µg Exenatide, prandial
Study: NCT04426708
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of HMS5552 25mg
Study: NCT01272557
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
Study: NCT04104646
Drug: CHF6563 matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual CHF6563 matched placebo administration
Study: NCT03523234
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoposide with cisplatin/carboplatin
Study: NCT00788957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion
Study: NCT02809183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension
Study: NCT02809183
Drug: TRC101
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension
Study: NCT02486796
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preparation of melatonin
Study: NCT03387098
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03387098
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03387098
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03387098
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT03345316
Drug: FFI-1010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single dosing
Study: NCT02740634
Drug: F-18 AV 1451
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tau binding agent
Study: NCT02875314
Drug: Induction
Normalized name: Intravenous induction agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
Study: NCT02875314
Drug: Single Cycle Intensive Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin, thiotepa, etoposide
Study: NCT04041609
Drug: LYR-210
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single administration of LYR-210 depot
Study: NCT04498923
Drug: Bupivacaine, dexamethasone, epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
Study: NCT00016926
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02068027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02048969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
Study: NCT00494299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: matching placebo
Study: NCT00113087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo
Study: NCT01222624
Drug: PankoMab-GEX™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03212690
Drug: Local standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
Study: NCT02350569
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally
Study: NCT02654847
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02654847
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution, used as a diluent.
Study: NCT03500848
Drug: MMF and/or steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
Study: NCT00456157
Drug: Intra-articular Injection of OP-1 to affected knee
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03505190
Drug: RO7062931
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
Study: NCT03505190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously (SC).
Study: NCT00202449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04365868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT01141452
Drug: Extra-fine hydrofluoroalkane beclomethasone MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-up in baseline BDP-equivalent ICS dose
Study: NCT01141452
Drug: Chlorofluorocarbon beclomethasone metered dose inhaler
Normalized name: beclomethasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-up in baseline BDP-equivalent ICS dose
Study: NCT01141452
Drug: Hydrofluoroalkane beclomethasone metred dose inhaler
Normalized name: beclomethasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of ICS therapy
Study: NCT00002532
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002532
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002532
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01634061
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
Study: NCT01634061
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
Study: NCT03904732
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
Study: NCT01330784
Drug: hMG-HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03202836
Drug: Tocolytics
Approvals — FDA: no, EMA: no, PMDA: no
Description: tocolysis for 48 hours
Study: NCT03202836
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: antenatal corticosteroids for 48 hours
Study: NCT00860288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02515396
Drug: MMI-0100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02515396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03015857
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - norepinephrine; a vasopressor drug given to prevent post spinal hypotension
Study: NCT04443530
Drug: Ultimaster™ Tansei™ stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving Ultimaster™ Tansei™ stents
Study: NCT04442906
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
Study: NCT03015857
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrathecal fentanyl 20 mcg will be given in both groups
Study: NCT04108234
Drug: HR071603
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR071603 monotherapy ,nasal spray
Study: NCT04108234
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo,nasal spray
Study: NCT02925117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00651391
Drug: Ezetimibe + Simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
Study: NCT00651391
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral simvastatin 20 mg once daily in the evening for 12 weeks
Study: NCT00651391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo once daily in the evening for 12 weeks
Study: NCT02007148
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: twice a day
Study: NCT02267057
Drug: Paracetamol placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
Study: NCT03265899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
Study: NCT02145975
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
Study: NCT00582036
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of sliding scale insulin as per Appendix 1
Study: NCT04561128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be subcutaneously administered with different dose levels
Study: NCT01596647
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Study: NCT01596647
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Study: NCT01596647
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Description: dovitinib, 5 days on / 2 days off dose schedule
Study: NCT03398044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to patients randomised into the control group arm.
Study: NCT03506789
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline
Study: NCT02784106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
Study: NCT03332329
Drug: Granulocyte Macrophage Colony Stimulating Factor
Normalized name: Granulocyte macrophage colony stimulating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
Study: NCT03332329
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60ug HBV vaccine is used every four week for 24 weeks
Study: NCT01989520
Drug: Phase IIb formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose 45mg AZD5069
Study: NCT01989520
Drug: Putative phase III formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose 45mg AZD5069
Study: NCT01989520
Drug: Test treatment E
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
Study: NCT00878254
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 800 mg/m\^2 IV on Day 1 and 200 mg/m\^2 IV on Days 2 through 5 of Cycles 1 and 3, per study protocol.
Study: NCT00878254
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 45 mg/m\^2 IV bolus Day 1 of Cycles 1 and 3, per study protocol.